Movement Alert｜SBP GROUP Falls 3.06% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus07-30

On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the pharmaceutical sector.

Within the Pharmaceuticals sector, peers declined in tandem: CSPC Pharma fell 2.63%, ASYMCHEM dropped 2.75%, HANSOH Pharma lost 1.67%, and HENGRUI Pharma slipped 0.34%. The sector-wide downturn weighed broadly on constituent stocks. Additionally, Nomura recently trimmed its target price for SBP GROUP from HK$8.67 to HK$8.26 while maintaining a Buy rating, with the consensus analyst mean target at HK$7.97 — still well above the current trading level.

Recent catalysts include the company establishing a 51%-owned joint venture with Indonesia's Tempo Scan on July 27 to deepen Southeast Asian market penetration, and obtaining clinical trial approval for its IM-101 hepatitis B drug on July 23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179593033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179593033","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SBP GROUP Falls 3.06% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure","media":"Market Focus","content":"<p><p>On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the pharmaceutical sector.</p><p>Within the Pharmaceuticals sector, peers declined in tandem: CSPC Pharma fell 2.63%, ASYMCHEM dropped 2.75%, HANSOH Pharma lost 1.67%, and HENGRUI Pharma slipped 0.34%. The sector-wide downturn weighed broadly on constituent stocks. Additionally, Nomura recently trimmed its target price for SBP GROUP from HK$8.67 to HK$8.26 while maintaining a Buy rating, with the consensus analyst mean target at HK$7.97 — still well above the current trading level.</p><p>Recent catalysts include the company establishing a 51%-owned joint venture with Indonesia's Tempo Scan on July 27 to deepen Southeast Asian market penetration, and obtaining clinical trial approval for its IM-101 hepatitis B drug on July 23.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SBP GROUP Falls 3.06% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SBP GROUP Falls 3.06% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the pharmaceutical sector.</p><p>Within the Pharmaceuticals sector, peers declined in tandem: CSPC Pharma fell 2.63%, ASYMCHEM dropped 2.75%, HANSOH Pharma lost 1.67%, and HENGRUI Pharma slipped 0.34%. The sector-wide downturn weighed broadly on constituent stocks. Additionally, Nomura recently trimmed its target price for SBP GROUP from HK$8.67 to HK$8.26 while maintaining a Buy rating, with the consensus analyst mean target at HK$7.97 — still well above the current trading level.</p><p>Recent catalysts include the company establishing a 51%-owned joint venture with Indonesia's Tempo Scan on July 27 to deepen Southeast Asian market penetration, and obtaining clinical trial approval for its IM-101 hepatitis B drug on July 23.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1179593033","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179593033","pubTimestamp":1785375784,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"走势警报|SBP集团常规交易下跌3.06%，制药板块面临广泛抛售压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On July 30, SBP GROUP declined 3.06% in regular trading, trading at 5.09 HKD/share with turnover of approximately 38.48 million HKD. The stock weakened amid broad-based selling pressure across the pharmaceutical sector.Within the Pharmaceuticals sector, peers declined in tandem: CSPC Pharma fell 2.63%, ASYMCHEM dropped 2.75%, HANSOH Pharma lost 1.67%, and HENGRUI Pharma slipped 0.34%. The sector-wide downturn weighed broadly on constituent stocks. Additionally, Nomura recently trimmed its target price for SBP GROUP from HK$8.67 to HK$8.26 while maintaining a Buy rating, with the consensus analyst mean target at HK$7.97 — still well above the current trading level.Recent catalysts include the company establishing a 51%-owned joint venture with Indonesia's Tempo Scan on July 27 to deepen Southeast Asian market penetration, and obtaining clinical trial approval for its IM-101 hepatitis B drug on July 23.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179593033","isCrawlerRequest":true}